This content is for healthcare professionals only.

Please confirm that you are a healthcare professional.

Decline

This activity has been funded by educational grants from Amgen Inc. and Adaptive Biotechnologies. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Leukaemia Watch Time: 46 mins

touchROUNDTABLE The role of measurable residual disease in acute lymphoblastic leukaemia

Watch leading experts Aaron Logan, Joseph Khoury and Nicola Gökbuget discuss the importance of measurable residual disease reporting in acute lymphoblastic lymphoma, as well as best practice techniques, potential limitations, and future directions.
Associate Prof. Aaron Logan

University of California San Francisco, CA, USA

CHAIR

Panelists:
Prof. Joseph Khoury, Dr Nicola Gökbuget
 
Video Chapters
Introduction

Associate Prof. Logan introduces the expert faculty and provides an overview of the meeting’s objectives.

view bio and disclosures
1/4 Next Chapter
 
Laboratory approach to measurable residual disease evaluation in acute lymphoblastic leukaemia

Prof. Khoury presents approaches to measuring residual disease in acute lymphoblastic leukaemia, and the expert faculty discuss challenges, gaps and reporting methods.

view bio and disclosures
2/4 Next Chapter
 
Clinical approach to measurable residual disease evaluation in acute lymphoblastic leukaemia

Associate Prof. Logan highlights the benefits of therapy guided by measurable residual disease testing, and the expert faculty discuss their own experiences and practices.

view bio and disclosures
3/4 Next Chapter
 
Future approaches to measurable residual disease evaluation in acute lymphoblastic leukaemia

Dr Gökbuget summarizes the current status of measurable residual disease testing, and discusses future developments with the group.

view bio and disclosures
4/4 Leave Feedback
Leave Feedback
Overview & Learning Objectives
Overview

Testing for measurable residual disease (MRD) in patients with acute lymphoblastic leukaemia (ALL) is an important part of the treatment decision-making process, as the presence of MRD is a strong predictor of survival and disease-free outcomes.1,2 In this activity, leading experts discuss not only how MRD-guided treatment can improve ALL patient outcomes, but also best practice techniques, potential limitations, and future directions.

Learning Objectives

After watching this activity, participants should be better able to:

  • Evaluate the evolving treatment landscape for acute lymphoblastic leukaemia
  • Appraise the benefits and limitations of performing and reporting results for measurable residual disease
  • Summarize how clinicians and pathologists can collaborate to use measurable residual disease testing to guide disease management
Faculty & Disclosures
Associate Prof. Aaron Logan

University of California San Francisco, CA, USA

Aaron Logan is Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF) and Director of the Hematologic Malignancies Tissue Bank at UCSF. His clinical practice focuses on the management of patients with acute leukaemia’s, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. His research areas include the application of immune repertoire profiling to quantify and track malignancy-, pathogen- and autoantigen-targeted immune responses following allogeneic transplantation, as well quantifying measurable residual disease in lymphoid malignancies.

Associate Prof. Aaron Logan disclosures: Research Funding from Amphivena, Astellas, Autolus, Jazz Pharmaceuticals, Kadmon, Kite and Pharmacyclics. Consulting: Amgen, Bristol-Meyers Squibb, Incyte and Pfizer.

Prof. Joseph Khoury

The University of Texas, MD Anderson Cancer Center Houston, TX, USA

Joseph Khoury is Associate Professor and Executive Director of the MD Anderson Cancer Network, Division of Pathology and Laboratory Medicine, University of Texas, MD Anderson Cancer Center, USA. Prof. Khoury is also Associate Editor of Cancer Medicine and is on the Editorial Board of the Journal of Cancer Stem Cell Research. His clinical and research interests lie in diagnostic pathology, translational research, and education. He has authored more than 120 publications and two textbooks, and has been an invited lecturer at numerous institutions and conferences across the USA and globally.

Prof. Khoury has no disclosures relating to this activity.

Dr Nicola Gökbuget

Johann Wolfgang Goethe-University, Medical Department II Frankfurt, Germany

Nicola Gökbuget is Professor of Hematology/Oncology at the Johann Wolfgang Goethe-University Medical Department II in Frankfurt, Germany. She is also Head of the Study Center and Scientific Task Force Director at the University Cancer Center in Frankfurt, Germany. For over 20 years she has served as the coordinator of the German Multicentre Study Group for Adult Acute Lymphoblastic Leukaemia (GMALL), which includes over 140 participating hospitals across Germany, and helped found a national registry for acute lymphoblastic leukaemia. She has also served as the co-ordinating or Principal Investigator of numerous academic or industry-sponsored clinical trials in adult acute lymphoblastic leukaemia and related diseases, such as lymphoblastic lymphoma or Burkitt’s lymphoma.

Dr Gökbuget has received speaker honoraria, travel support or advisory board honoraria from Amgen, Celgene, Cellestia, Erytech, Gilead, Incyte, Jazz Pharmaceuticals, Morphosys, Novartis, and Pfizer. She has also received research support from Amgen, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, and Shire/Servier.

References
References
  1. Berry DA, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukaemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.
  2. Brüggemann M, Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukaemia. Blood. 2006;107:1116–23.
Downloads

View and download resources from this activity to support your learning or share with colleagues.

Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights.
Register For Free Now
Feedback Close
Feedback

Please provide feedback for this touchROUNDTABLE on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72